Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea

NCT02555761 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT02555761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02555761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea
Lead sponsor
Allergan
Phase
Observational
Overall status
Completed
Start date
October 19, 2015
Completion date
March 19, 2018
Enrollment
3,423 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

conjunctivitis, allergic